TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2397543

Group type: EXPERIMENTAL
Intervention: Traditional Chinese Medicine (TCM) treatment with herbs: Bupleurum chinense, Scutellaria baicalensis, Astragalus membranaceus, Codonopsis pilosula, Ligustrum lucidum, Lophatherum gracile, and thread of ivory, for 1-3 courses of treatment lasting one month each.
Number of subjects: 100

Group type: COMPARATOR
Intervention: Western Medicine (WM) treatment with retalin 5-15 mg twice daily, for 1-3 courses of treatment lasting one month each.
Number of subjects: 100
Study: 31063

Group type: EXPERIMENTAL
Intervention: Lorazepam 5 mg
Number of subjects: 18

Group type: COMPARATOR
Intervention: Diazepam 10 mg
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 18
Study: 28647684

Group type: EXPERIMENTAL
Intervention: Anti-H. pylori treatment at baseline
Number of subjects: 795

Group type: EXPERIMENTAL
Intervention: Continuous H. pylori infection for 16 years
Number of subjects: 795

Group type: EXPERIMENTAL
Intervention: Incomplete-type IM
Number of subjects: 795

Group type: EXPERIMENTAL
Intervention: Cumulative time of infection
Number of subjects: 795
Study: 25521438

Group type: EXPERIMENTAL
Intervention: State mandated private insurance coverage of CRC screening
Number of subjects: 0

Group type: COMPARATOR
Intervention: No mandate
Number of subjects: 0
Study: 24600204

Group type: EXPERIMENTAL
Intervention: Olmesartan (20 mg once daily for 16 weeks)
Number of subjects: 317

Group type: COMPARATOR
Intervention: Candesartan (8 mg once daily for 16 weeks)
Number of subjects: 317

Group type: COMPARATOR
Intervention: Telmisartan (40 mg once daily for 16 weeks)
Number of subjects: 317
Study: 22257505

Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training using Threshold IMT device (G-1; n = 16)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Biofeedback (G-2; n = 15)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control group (n = 10)
Number of subjects: 41
Study: 19963436

Group type: EXPERIMENTAL
Intervention: Venlafaxine 75 mg daily
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: Cyproterone acetate 100 mg daily
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate 20 mg daily
Number of subjects: 311
Study: 18295343

Group type: EXPERIMENTAL
Intervention: Quetiapine switch (mean dose=290.0 mg/day, S.D.=55.2)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Risperidone continuation (mean dose=4.1 mg/day, S.D.=1.2)
Number of subjects: 42
Study: 15993359

Group type: EXPERIMENTAL
Intervention: 20 microg Diamyd
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: 500 microg Diamyd
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: All dose groups
Number of subjects: 47
Study: 11485375

Group type: EXPERIMENTAL
Intervention: L-NMMA alone
Number of subjects: 15

Group type: COMPARATOR
Intervention: BQ-123 alone
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: L-NMMA with BQ-123
Number of subjects: 15
Study: 9988537

Group type: EXPERIMENTAL
Intervention: liarozole
Number of subjects: 20

Group type: COMPARATOR
Intervention: acitretin
Number of subjects: 20
Study: 7906104

Group type: COMPARATOR
Intervention: Intramuscular diclofenac sodium 1 mg.kg‐1
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Caudal bupivacaine 0.25% 1 ml.kg‐1
Number of subjects: 250

Group type: COMPARATOR
Intervention: Control group (no analgesia)
Number of subjects: 250
Study: 3134208

Group type: EXPERIMENTAL
Intervention: Ceftazidime sodium carbonate
Number of subjects: 100

Group type: COMPARATOR
Intervention: Ceftazidime arginine
Number of subjects: 100
Study: 1870380

Group type: EXPERIMENTAL
Intervention: Single dose of rifampicin 1500 mg followed by one year of daily dapsone 100 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Single dose of rifampicin 40 mg/K bodyweight
Number of subjects: 0
Study: 320956

Group type: EXPERIMENTAL
Intervention: Lithium carbonate (mean serum level 0.91 mEq/liter)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 31509979

Group type: EXPERIMENTAL
Intervention: Raw Orange (RO)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 100% Fresh Orange Juice (FOJ)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Nectar-Sweetened Orange Juice (NSOJ)
Number of subjects: 20
Study: 28666463

Group type: EXPERIMENTAL
Intervention: Adjunctive treatment by homeopaths
Number of subjects: 566

Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 566
Study: 26460291

Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy (CEA)
Number of subjects: 821
Study: 23965181

Group type: EXPERIMENTAL
Intervention: Fondaparinux 2.5 mg once daily
Number of subjects: 1349

Group type: COMPARATOR
Intervention: Nadroparin 2850 anti-factor Xa IU once daily
Number of subjects: 1349

Group type: EXPERIMENTAL
Intervention: Fondaparinux
Number of subjects: 1349

Group type: COMPARATOR
Intervention: Nadroparin
Number of subjects: 1349
Study: 21862001

Group type: COMPARATOR
Intervention: Mock TEAS treatment (group I, n = 99)
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: Single TEAS treatment (group II, n = 110)
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: Double TEAS treatments (group III, n = 100)
Number of subjects: 309
Study: 19363330

Group type: EXPERIMENTAL
Intervention: PI/r and NNRTI
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: PI/r and NRTIs
Number of subjects: 71

Group type: COMPARATOR
Intervention: NNRTI and NRTIs
Number of subjects: 71
Study: 17805062

Group type: EXPERIMENTAL
Intervention: Irinotecan (60 mg/m2) and Cisplatin (75 mg/m2)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Sequential Docetaxel (75 mg/m2)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Irinotecan and Cisplatin (IC)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Sequential Docetaxel
Number of subjects: 46
Study: 15070418

Group type: EXPERIMENTAL
Intervention: Methylphenidate 1 mg/kg/day + zinc sulfate 55 mg/day (with approximately 15 mg zinc element)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Methylphenidate 1 mg/kg/day + placebo (sucrose 55 mg)
Number of subjects: 44
Study: 12227888

Group type: EXPERIMENTAL
Intervention: Triptorelin (Decapeptyl) and goserelin (Zoladex) - GnRH agonists, 4-month treatment course
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group - untreated patients
Number of subjects: 52
Study: 15010722

Group type: EXPERIMENTAL
Intervention: Zafirlukast (20 mg twice daily)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pranlukast (450 mg twice daily)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Montelukast
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Zileuton (leukotriene synthesis inhibitor)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PDE inhibitors
Number of subjects: 0
Study: 7722992

Group type: EXPERIMENTAL
Intervention: Treatment matching process assessment
Number of subjects: 0
Study: 2513206

Group type: EXPERIMENTAL
Intervention: Propranolol 160 mg/day
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Diltiazem 240 mg/day
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Nicardipine 80 mg/day
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Nifedipine 40 to 80 mg/day
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Verapamil 320 mg/day
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 5303665

Group type: EXPERIMENTAL
Intervention: Group A: one dose of 1 ml of cholera El Tor vaccine containing 8 x 10(9) organisms/ml
Number of subjects: 359600

Group type: EXPERIMENTAL
Intervention: Group B: 2 doses (1 ml each) of cholera El Tor vaccine containing 8 x 10(9) organisms/ml
Number of subjects: 359600

Group type: EXPERIMENTAL
Intervention: Group C: one dose of cholera El Tor vaccine containing 16 x 10(9) organisms/ml
Number of subjects: 359600

Group type: COMPARATOR
Intervention: Group D: 2 doses of typhoid vaccine
Number of subjects: 359600
Study: 31862217

Group type: EXPERIMENTAL
Intervention: Erector Spinae Plane Block (ESPB)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Quadratus Lumborum block type II (QLB‐II)
Number of subjects: 80
Study: 31221888

Group type: EXPERIMENTAL
Intervention: rhinothermy delivered by nasal high flow therapy (rNHF) at 41°C for 2 hours daily for five days
Number of subjects: 170

Group type: COMPARATOR
Intervention: sham rhinothermy for five days
Number of subjects: 170
Study: 27883211

Group type: EXPERIMENTAL
Intervention: Cortical porcine bone (cort)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Collagenated cortico‐cancellous (coll)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Natural healing (nat)
Number of subjects: 90
Study: 26307618

Group type: EXPERIMENTAL
Intervention: GoActive intervention
Number of subjects: 31
Study: 23874533

Group type: EXPERIMENTAL
Intervention: Nei Yang Gong (experimental group)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Progressive Muscle Relaxation (PMR) (control group)
Number of subjects: 46
Study: 21810497

Group type: EXPERIMENTAL
Intervention: Harmonic Focus
Number of subjects: 34

Group type: COMPARATOR
Intervention: Clamp-and-tie technique
Number of subjects: 34
Study: 19254600

Group type: EXPERIMENTAL
Intervention: Dual-task training with fixed-priority instructions
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Dual-task training with variable-priority instructions
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Single-task training
Number of subjects: 23

Group type: COMPARATOR
Intervention: All groups (including control)
Number of subjects: 23
Study: 16708634

Group type: EXPERIMENTAL
Intervention: Natural coffee (unfiltered)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Modified coffee (with reduced irritants)
Number of subjects: 36
Study: 14975486

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents (SESs)
Number of subjects: 369

Group type: COMPARATOR
Intervention: Bare stents
Number of subjects: 369
Study: 11106873

Group type: EXPERIMENTAL
Intervention: 0.25 mg/kg mCPP (low dose)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg mCPP (standard dose)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 9596311

Group type: EXPERIMENTAL
Intervention: 60 U of bleomycin sclerotherapy
Number of subjects: 106

Group type: COMPARATOR
Intervention: 500 mg of doxycycline sclerotherapy
Number of subjects: 106
Study: 7843980

Group type: EXPERIMENTAL
Intervention: Stages of change for dietary fat intake
Number of subjects: 17121

Group type: EXPERIMENTAL
Intervention: Stages of change for dietary fiber intake
Number of subjects: 17121

Group type: EXPERIMENTAL
Intervention: Stage of change
Number of subjects: 17121

Group type: COMPARATOR
Intervention: Demographic characteristics
Number of subjects: 17121
Study: 3211079

Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Sodium thiopentone
Number of subjects: 60
Study: 30646122

Group type: EXPERIMENTAL
Intervention: Consolidated NICE rule (predictive algorithm for delirium)
Number of subjects: 39377

Group type: EXPERIMENTAL
Intervention: Consolidated NICE rule
Number of subjects: 39377

Group type: COMPARATOR
Intervention: eNICE rule
Number of subjects: 39377

Group type: COMPARATOR
Intervention: Pendlebury NICE rule
Number of subjects: 39377
Study: 27483320

Group type: EXPERIMENTAL
Intervention: Higher fat mass index
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: Higher fat-free mass index
Number of subjects: 303
Study: 24928284

Group type: EXPERIMENTAL
Intervention: Pikasol® (3 capsules per day, 1.8 g EPA + DHA)
Number of subjects: 1400

Group type: COMPARATOR
Intervention: Placebo (corn oil)
Number of subjects: 1400
Study: 23741829

Group type: EXPERIMENTAL
Intervention: Lincomycin hydrochloride 500 mg capsules
Number of subjects: 41

Group type: COMPARATOR
Intervention: Cefpodoxime proxetil 200 mg tablets
Number of subjects: 41
Study: 20979799

Group type: EXPERIMENTAL
Intervention: Inhaled tiotropium 18 µg once daily
Number of subjects: 205

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 205
Study: 18757956

Group type: EXPERIMENTAL
Intervention: Fixed-bearing total knee replacement
Number of subjects: 242

Group type: COMPARATOR
Intervention: Mobile-bearing total knee replacement
Number of subjects: 242
Study: 16358136

Group type: EXPERIMENTAL
Intervention: Positive end expiratory pressure (PEEP) associated with physiotherapy intervention (GEP)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Physiotherapy intervention alone (GPI)
Number of subjects: 24
Study: 12461499

Group type: EXPERIMENTAL
Intervention: Epinephrine (EPI)
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Albuterol (ALB)
Number of subjects: 149

Group type: COMPARATOR
Intervention: Saline placebo (PLAC)
Number of subjects: 149
Study: 10361658

Group type: EXPERIMENTAL
Intervention: Current cigarette smoking
Number of subjects: 3222

Group type: COMPARATOR
Intervention: No smoking (control group)
Number of subjects: 3222
Study: 8775626

Group type: EXPERIMENTAL
Intervention: Operated group (n = 12)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Unoperated group (n = 8)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Reference group (n = 46)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Operated group (n = 26)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Unoperated group (n = 22)
Number of subjects: 48
Study: 2343912

Group type: EXPERIMENTAL
Intervention: 16-week treatment conditions (specifics not provided)
Number of subjects: 239
Study: 7003855

Group type: EXPERIMENTAL
Intervention: Diethylcarbamazine (DEC) lotion, applied daily for seven days, then weekly for seven weeks
Number of subjects: 187

Group type: COMPARATOR
Intervention: Placebo lotion
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Diethylcarbamazine (DEC) lotion
Number of subjects: 187
Study: 31544378

Group type: EXPERIMENTAL
Intervention: Acupuncture and moxibustion therapy of Tiaochongren Gushenyuan
Number of subjects: 80

Group type: COMPARATOR
Intervention: Routine acupuncture and moxibustion (control group)
Number of subjects: 80
Study: 29037576

Group type: EXPERIMENTAL
Intervention: Maternal vaccination during pregnancy (not specified dosage or duration)
Number of subjects: 291
Study: 26902229

Group type: EXPERIMENTAL
Intervention: Blinded capnography alarm
Number of subjects: 452

Group type: COMPARATOR
Intervention: Open capnography alarm
Number of subjects: 452
Study: 23379385

Group type: EXPERIMENTAL
Intervention: Intrusive thoughts about cancer
Number of subjects: 558
Study: 22825036

Group type: EXPERIMENTAL
Intervention: I-131 therapy (less than 11.1 GBq)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: I-131 therapy (11.1 GBq or more)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Control group (no I-131 therapy)
Number of subjects: 98
Study: 20413078

Group type: EXPERIMENTAL
Intervention: Youth Risk Behavior Surveillance System (YRBSS)
Number of subjects: 677

Group type: EXPERIMENTAL
Intervention: YRBSS problem behaviors (conduct problems, sexual behavior, suicide/hopelessness)
Number of subjects: 677

Group type: EXPERIMENTAL
Intervention: Demographic analysis of YRBSS subdomain scaling
Number of subjects: 677
Study: 18285589

Group type: COMPARATOR
Intervention: Annual mass azithromycin administration
Number of subjects: 16803

Group type: EXPERIMENTAL
Intervention: Biannual mass azithromycin administration
Number of subjects: 16803
Study: 16355608

Group type: EXPERIMENTAL
Intervention: Changji' an (CJA) oral liquid
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 24
Study: 12804182

Group type: EXPERIMENTAL
Intervention: ATG treatment for GVHD prophylaxis
Number of subjects: 38

Group type: COMPARATOR
Intervention: No ATG treatment for GVHD prophylaxis
Number of subjects: 38
Study: 10588209

Group type: EXPERIMENTAL
Intervention: 50-mg bolus of recombinant tissue-type plasminogen activator (rt-PA)
Number of subjects: 606

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 606

Group type: EXPERIMENTAL
Intervention: Rescue and primary PTCA
Number of subjects: 606

Group type: EXPERIMENTAL
Intervention: rt-PA
Number of subjects: 606

Group type: EXPERIMENTAL
Intervention: Angioplasty after rt-PA
Number of subjects: 606

Group type: EXPERIMENTAL
Intervention: rt-PA and placebo
Number of subjects: 606
Study: 9110470

Group type: EXPERIMENTAL
Intervention: Peripheral nerve conduction study in lead workers
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (randomized)
Number of subjects: 20
Study: 8475268

Group type: EXPERIMENTAL
Intervention: Biphasic injection protocol
Number of subjects: 105

Group type: COMPARATOR
Intervention: Uniphasic injection protocol
Number of subjects: 105
Study: 3515926

Group type: EXPERIMENTAL
Intervention: 50 mg of oral flurbiprofen
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: 10 mg of intramuscular morphine sulfate
Number of subjects: 92

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study: 31564356

Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept injection on a monthly basis for 3 months, followed by bimonthly injections for another 9 months.
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept injection
Number of subjects: 36
Study: 31047350

Group type: EXPERIMENTAL
Intervention: Ranibizumab (0.3 mg or 0.5 mg)
Number of subjects: 759

Group type: COMPARATOR
Intervention: Sham injections
Number of subjects: 759
Study: 27681009

Group type: EXPERIMENTAL
Intervention: Housing First
Number of subjects: 156

Group type: COMPARATOR
Intervention: Treatment as usual (Control)
Number of subjects: 156
Study: 24777811

Group type: EXPERIMENTAL
Intervention: Ezetimibe 10 mg
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg/ezetimibe 10 mg
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control (Atorvastatin 10 mg during run-in period)
Number of subjects: 63
Study: 24659566

Group type: EXPERIMENTAL
Intervention: Clarithromycin 250 mg/day for 12 weeks
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Clarithromycin 250 mg/day for 24 weeks
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control group (no clarithromycin)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Clarithromycin groups (both 12 and 24 weeks)
Number of subjects: 66
Study: 23003211

Group type: EXPERIMENTAL
Intervention: Lateral table tilt
Number of subjects: 35

Group type: COMPARATOR
Intervention: Pelvic wedge
Number of subjects: 35
Study: 18622878

Group type: EXPERIMENTAL
Intervention: Ibuprofen foam treatment (n = 98)
Number of subjects: 185

Group type: COMPARATOR
Intervention: Local best practice (n = 87)
Number of subjects: 185
Study: 17908130

Group type: EXPERIMENTAL
Intervention: Complex intervention with treatment fidelity procedures (specific details on dosage and duration not available)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Treatment fidelity procedures applied in the SPHERE study
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Behavior Change Consortium's model of treatment fidelity
Number of subjects: 0
Study: 14684407

Group type: EXPERIMENTAL
Intervention: Daily oral doses of 100 mg elemental Fe and 500 micro g folic acid
Number of subjects: 100

Group type: COMPARATOR
Intervention: 3 intramuscular doses of 250 mg elemental Fe as iron dextran at 1‐mo intervals and oral doses of 5 mg folic acid twice weekly
Number of subjects: 100
Study: 11748974

Group type: EXPERIMENTAL
Intervention: Fibrin glue
Number of subjects: 93

Group type: COMPARATOR
Intervention: No fibrin glue (Control)
Number of subjects: 93
Study: 9658755

Group type: EXPERIMENTAL
Intervention: Skin-mounted accelerometer
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gait analysis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ankle fixation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Simulation using a rigid-body model
Number of subjects: 0
Study: 8677931

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg for 4 weeks plus amoxycillin 3 g daily and metronidazole 1 g daily during the 2nd and 3rd week (group A)
Number of subjects: 183

Group type: COMPARATOR
Intervention: Matching placebo (group B)
Number of subjects: 183
Study: 1761941

Group type: EXPERIMENTAL
Intervention: Sheehy collar button ventilation tube
Number of subjects: 0

Group type: COMPARATOR
Intervention: Shepard tube
Number of subjects: 0
Study: 6121479

Group type: EXPERIMENTAL
Intervention: Intravenous atenolol (5 mg) followed by oral atenolol (50 mg)
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Intravenous atenolol (5 to 15 mg)
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 203

Group type: COMPARATOR
Intervention: No beta blockade
Number of subjects: 203
Study: 31191106

Group type: EXPERIMENTAL
Intervention: Dynamic Stretching (DS)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Static Stretching (SS)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Submaximal Isometric Muscle Activity (SIMA)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control Condition
Number of subjects: 13
Study: 28065557

Group type: EXPERIMENTAL
Intervention: Manual laryngeal fixation (MLF) with Macintosh laryngoscope (McL)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Manual laryngeal fixation (MLF) with McGRATH® MAC (McGRGTH)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Manual laryngeal fixation (MLF) with Pentax‐AWS Airwayscope® (AWS)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Without manual laryngeal fixation (MLF) with Macintosh laryngoscope (McL)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Without manual laryngeal fixation (MLF) with McGRATH® MAC (McGRGTH)
Number of subjects: 31
Study: 27236886

Group type: EXPERIMENTAL
Intervention: TCM clinical outcomes rating scale for HF (TCM‐HF‐PRO)
Number of subjects: 340

Group type: COMPARATOR
Intervention: Control group (not specified what intervention was used)
Number of subjects: 340
Study: 24411226

Group type: EXPERIMENTAL
Intervention: External beam radiotherapy
Number of subjects: 227
Study: 22709810

Group type: EXPERIMENTAL
Intervention: High reduced-fat dairy, cereal, nuts, and fruits dietary pattern (rural)
Number of subjects: 729

Group type: EXPERIMENTAL
Intervention: Mixed dietary pattern (rural)
Number of subjects: 729

Group type: EXPERIMENTAL
Intervention: High fruits and vegetables dietary pattern (urban)
Number of subjects: 729
Study: 19238808

Group type: EXPERIMENTAL
Intervention: Caffeine, 600 mg (n=12)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Modafinil, 400 mg (n=12)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Dextroamphetamine, 20 mg (n=16)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo (n=14)
Number of subjects: 54
Study: 17303771

Group type: EXPERIMENTAL
Intervention: Activate‐Initiate‐Monitor care management program
Number of subjects: 188

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 188